



Tes Pharma Announces Renewal of Research and Development Collaboration with Intercept Pharmaceuticals

Solomeo-Corciano (PG), Italy, January 14 – Tes Pharma, a biotech company focused on delivering first-in-class therapeutics for high unmet medical needs in oncology, renal and metabolic diseases, today announced the renewal of its research and development collaboration with Intercept Pharmaceuticals, Inc. (Intercept), a wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases.

As part of the collaboration, which began in 2015, Intercept purchased from Tes Pharma the rights to INT-787, a selective next generation Farnesoid X Receptor (FXR) agonist that showed strong anti-fibrotic and anti-inflammatory effects in animal models and is currently in clinical development for the treatment of severe alcohol-associated hepatitis (sAH).

Professor Roberto Pellicciari, founder and Chief Scientific Advisor of Tes Pharma, commented as follows: *“We are very pleased on the renewal of the collaboration with Intercept. The success of this long-standing collaboration encourages us to continue our mission to find new treatments to help improve people’s lives, especially for patients suffering from serious diseases.”*

About Tes Pharma

Tes Pharma is a biotech company focused on delivering first-in-class therapeutics for high unmet medical needs in metabolic, renal diseases and oncology. Tes Pharma’s clinically validated drug discovery engine generates rationally designed drug candidates for novel targets. Tes Pharma has a long-standing partnership with Intercept for the discovery and development of bile acid derivatives for the treatment of liver disease. INT-787 is undergoing Phase 2 clinical studies for the treatment of severe alcohol-associated hepatitis (sAH). Separate from the collaboration with Intercept, Tes Pharma is also developing TES-AKI-01 and TES-ONC-07, two first-in-class small molecules for the treatment of acute kidney injury and for cancer immunotherapy, respectively, that are entering IND-enabling studies. Also, Tes Pharma has an undisclosed pipeline of additional projects in the early phase of drug discovery.

For more information, please visit www.tespharma.com or connect with the Company on [LinkedIn](#)

About Intercept

Intercept Pharmaceuticals, Inc. is a wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). For more information, please visit www.interceptpharma.com or connect with the Company on [LinkedIn](#), [Threads](#) and [X \(formerly Twitter\)](#).



For further information, please contact:

Sara Malincarne
smalincarne@tespharma.com
www.tespharma.com